<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38932130</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>SPIKENET: An Evidence-Based Therapy for Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">838</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16060838</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has been one of the most impactful events in our lifetime, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple SARS-CoV-2 variants were reported globally, and a wide range of symptoms existed. Individuals who contract COVID-19 continue to suffer for a long time, known as long COVID or post-acute sequelae of COVID-19 (PASC). While COVID-19 vaccines were widely deployed, both unvaccinated and vaccinated individuals experienced long-term complications. To date, there are no treatments to eradicate long COVID. We recently conceived a new approach to treat COVID in which a 15-amino-acid synthetic peptide (SPIKENET, SPK) is targeted to the ACE2 receptor binding domain of SARS-CoV-2, which prevents the virus from attaching to the host. We also found that SPK precludes the binding of spike glycoproteins with the receptor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) of a coronavirus, murine hepatitis virus-1 (MHV-1), and with all SARS-CoV-2 variants. Further, SPK reversed the development of severe inflammation, oxidative stress, tissue edema, and animal death post-MHV-1 infection in mice. SPK also protects against multiple organ damage in acute and long-term post-MHV-1 infection. Our findings collectively suggest a potential therapeutic benefit of SPK for treating COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elumalai</LastName><ForeName>Nila</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0008-8001-6235</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Hussain</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, HCA Florida Kendall Hospital, Miami, FL 33175, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampath</LastName><ForeName>Natarajan</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9237-5501</Identifier><AffiliationInfo><Affiliation>School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613401, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shamaladevi</LastName><ForeName>Nagarajarao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Molecular Analytics, Miami, FL 33187, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hajjar</LastName><ForeName>Rima</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9844-5176</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druyan</LastName><ForeName>Brian Zachary</ForeName><Initials>BZ</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashed</LastName><ForeName>Amirah B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0009-0009-1977-1503</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Rajalakshmi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6992-0612</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenyon</LastName><ForeName>Norma S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Microbiology &amp; Immunology and Biomedical Engineering, Diabetes Research Institute, University of Miami, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayakumar</LastName><ForeName>Arumugam R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0009-0009-2115-7860</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paidas</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>0000</GrantID><Agency>University of Miami Miller School of Medicine Department Obstetrics, Gynecology and Repro-ductive Sciences</Agency><Country/></Grant><Grant><GrantID>0000</GrantID><Agency>Muriel, Murray &amp; Robert Smith Foundation COVID-19 Research Fund</Agency><Country/></Grant><Grant><GrantID>0000</GrantID><Agency>University of Miami Miller School of Medicine Team Science Award</Agency><Country/></Grant><Grant><GrantID>0000</GrantID><Agency>Charles M. Vallee Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SPIKENET</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">molecular mechanism</Keyword><Keyword MajorTopicYN="N">multiorgan dysfunction</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>All authors have no conflicts of interest or competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38932130</ArticleId><ArticleId IdType="pmc">PMC11209161</ArticleId><ArticleId IdType="doi">10.3390/v16060838</ArticleId><ArticleId IdType="pii">v16060838</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Who Coronavirus (COVID-19) Dashboard.  [(accessed on 10 February 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  SARS-CoV-2 Variant Classifications and Definitions.  [(accessed on 10 February 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html.</Citation></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2. Erratum in Nat. Rev. Microbiol. 2023, 21, 408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldera-Crespo L.A., Paidas M.J., Roy S., Schulman C.I., Kenyon N.S., Daunert S., Jayakumar A.R. Experimental Models of COVID-19. Front. Cell. Infect. Microbiol. 2022;11:792584. doi: 10.3389/fcimb.2021.792584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.792584</ArticleId><ArticleId IdType="pmc">PMC8791197</ArticleId><ArticleId IdType="pubmed">35096645</ArticleId></ArticleIdList></Reference><Reference><Citation>Baj J., Karaku&#x142;a-Juchnowicz H., Teresi&#x144;ski G., Buszewicz G., Ciesielka M., Sitarz R., Forma A., Karaku&#x142;a K., Flieger W., Portincasa P., et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J. Clin. Med. 2020;9:1753. doi: 10.3390/jcm9061753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061753</ArticleId><ArticleId IdType="pmc">PMC7356953</ArticleId><ArticleId IdType="pubmed">32516940</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodebaugh T.L., Frumkin M.R., Reiersen A.M., Lenze E.J., Avidan M.S., Miller J.P., Piccirillo J.F., Zorumski C.F., Mattar C. Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time. Open Forum Infect. Dis. 2021;8:ofab090. doi: 10.1093/ofid/ofab090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab090</ArticleId><ArticleId IdType="pmc">PMC7989225</ArticleId><ArticleId IdType="pubmed">33796601</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Paidas M.J., Cosio D.S., Ali S., Kenyon N.S., Jayakumar A.R. Long-Term Sequelae of COVID-19 in Experimental Mice. Mol. Neurobiol. 2022;59:5970&#x2013;5986. doi: 10.1007/s12035-022-02932-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-022-02932-1</ArticleId><ArticleId IdType="pmc">PMC9281331</ArticleId><ArticleId IdType="pubmed">35831558</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Treatments and Medications.  [(accessed on 10 February 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Long COVID or Post-COVID Conditions.  [(accessed on 10 February 2024)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Scialo F., Daniele A., Amato F., Pastore L., Matera M.G., Cazzola M., Castaldo G., Bianco A. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020;198:867&#x2013;877. doi: 10.1007/s00408-020-00408-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-020-00408-4</ArticleId><ArticleId IdType="pmc">PMC7653219</ArticleId><ArticleId IdType="pubmed">33170317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Paidas M.J., Sampath N., Schindler E.A., Cosio D.S., Ndubizu C.O., Shamaladevi N., Kwal J., Rodriguez S., Ahmad A., Kenyon N.S., et al. Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide. Front. Pharmacol. 2022;13:864798. doi: 10.3389/fphar.2022.864798.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.864798</ArticleId><ArticleId IdType="pmc">PMC9196045</ArticleId><ArticleId IdType="pubmed">35712703</ArticleId></ArticleIdList></Reference><Reference><Citation>Masciarella A.D., Di Gregorio D.M., Ramamoorthy R., Hussain H., Jayakumar A.R., Paidas M.J. A Mouse Model of MHV-1 Virus Infection for Study of Acute and Long COVID Infection. Curr. Protoc. 2023;3:e896. doi: 10.1002/cpz1.896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.896</ArticleId><ArticleId IdType="pmc">PMC10606938</ArticleId><ArticleId IdType="pubmed">37867460</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira G.P., Kroon E.G. Mouse hepatitis virus: A betacoronavirus model to study the virucidal activity of air disinfection equipment on surface contamination. J. Virol. Methods. 2021;297:114274. doi: 10.1016/j.jviromet.2021.114274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114274</ArticleId><ArticleId IdType="pmc">PMC8404383</ArticleId><ArticleId IdType="pubmed">34474071</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanolkar A., Pewe L., Tifrea D., Perlman S., Harty J.T. Developing MHV-1 infection as an animal model for severe acute respiratory syndrome (SARS) (43.30) J. Immunol. 2007;178((Suppl. S1)):S42. doi: 10.4049/jimmunol.178.Supp.43.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.Supp.43.30</ArticleId></ArticleIdList></Reference><Reference><Citation>De Albuquerque N., Baig E., Ma X., Zhang J., He W., Rowe A., Habal M., Liu M., Shalev I., Downey G.P., et al. Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. J. Virol. 2006;80:10382&#x2013;10394. doi: 10.1128/JVI.00747-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00747-06</ArticleId><ArticleId IdType="pmc">PMC1641767</ArticleId><ArticleId IdType="pubmed">17041219</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips J.M., Weiss S.R. Pathogenesis of neurotropic murine coronavirus is multifactorial. Trends Pharmacol. Sci. 2011;32:2&#x2013;7. doi: 10.1016/j.tips.2010.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2010.11.001</ArticleId><ArticleId IdType="pmc">PMC3022387</ArticleId><ArticleId IdType="pubmed">21144598</ArticleId></ArticleIdList></Reference><Reference><Citation>Benny M., Bandstra E.S., Saad A.G., Lopez-Alberola R., Saigal G., Paidas M.J., Jayakumar A.R., Duara S. Maternal SARS-CoV-2, Placental Changes and Brain Injury in 2 Neonates. Pediatrics. 2023;151:e2022058271. doi: 10.1542/peds.2022-058271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-058271</ArticleId><ArticleId IdType="pmc">PMC10467358</ArticleId><ArticleId IdType="pubmed">37021494</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy R., Hussain H., Ravelo N., Sriramajayam K., Di Gregorio D.M., Paulrasu K., Chen P., Young K., Masciarella A.D., Jayakumar A.R., et al. Kidney Damage in Long COVID: Studies in Experimental Mice. Biology. 2023;12:1070. doi: 10.3390/biology12081070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology12081070</ArticleId><ArticleId IdType="pmc">PMC10452084</ArticleId><ArticleId IdType="pubmed">37626956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain H., Paidas M.J., Ramamoorthy R., Fadel A., Ali M., Chen P., Jayakumar A.R. Dermatologic Changes in Experimental Model of Long COVID. Microorganisms. 2024;2:272. doi: 10.3390/microorganisms12020272.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms12020272</ArticleId><ArticleId IdType="pmc">PMC10892887</ArticleId><ArticleId IdType="pubmed">38399677</ArticleId></ArticleIdList></Reference><Reference><Citation>Forcados G.E., Muhammad A., Oladipo O.O., Makama S., Meseko C.A. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. Front. Cell. Infect. Microbiol. 2021;11:654813. doi: 10.3389/fcimb.2021.654813.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.654813</ArticleId><ArticleId IdType="pmc">PMC8188981</ArticleId><ArticleId IdType="pubmed">34123871</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson I., Karlsson M., Shukla V.K., Chrispeels M.J., Larsson C., Kjellbom P. Water transport activity of the plasma membrane aquaporin PM28A is regulated by phosphorylation. Plant Cell. 1998;10:451&#x2013;459. doi: 10.1105/tpc.10.3.451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1105/tpc.10.3.451</ArticleId><ArticleId IdType="pmc">PMC144000</ArticleId><ArticleId IdType="pubmed">9501117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T., Yang B., Gillespie A., Carlson E.J., Epstein C.J., Verkman A.S. Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J. Clin. Investig. 1997;100:957&#x2013;962. doi: 10.1172/JCI231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI231</ArticleId><ArticleId IdType="pmc">PMC508270</ArticleId><ArticleId IdType="pubmed">9276712</ArticleId></ArticleIdList></Reference><Reference><Citation>Rama Rao K.V., Jayakumar A.R., Tong X., Curtis K.M., Norenberg M.D. Brain aquaporin-4 in experimental acute liver failure. J. Neuropathol. Exp. Neurol. 2010;69:869&#x2013;879. doi: 10.1097/NEN.0b013e3181ebe581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181ebe581</ArticleId><ArticleId IdType="pmc">PMC4737434</ArticleId><ArticleId IdType="pubmed">20720509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittekindt O.H., Dietl P. Aquaporins in the lung. Pflug. Arch. 2019;4:519&#x2013;532. doi: 10.1007/s00424-018-2232-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00424-018-2232-y</ArticleId><ArticleId IdType="pmc">PMC6435619</ArticleId><ArticleId IdType="pubmed">30397774</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataraman T., Frieman M.B. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antivir. Res. 2017;143:142&#x2013;150. doi: 10.1016/j.antiviral.2017.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.03.022</ArticleId><ArticleId IdType="pmc">PMC5507769</ArticleId><ArticleId IdType="pubmed">28390872</ArticleId></ArticleIdList></Reference><Reference><Citation>Schramm F., Schaefer L., Wygrecka M. EGFR Signaling in Lung Fibrosis. Cells. 2022;11:986. doi: 10.3390/cells11060986.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11060986</ArticleId><ArticleId IdType="pmc">PMC8947373</ArticleId><ArticleId IdType="pubmed">35326439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Chen J.K., Nagai K., Plieth D., Tan M., Lee T.C., Threadgill D.W., Neilson E.G., Harris R.C. EGFR signaling promotes TGF&#x3b2;-dependent renal fibrosis. J. Am. Soc. Nephrol. 2012;23:215&#x2013;224. doi: 10.1681/ASN.2011070645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2011070645</ArticleId><ArticleId IdType="pmc">PMC3269185</ArticleId><ArticleId IdType="pubmed">22095949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisto M., Ribatti D., Lisi S. Organ Fibrosis and Autoimmunity; The Role of Inflammation in TGF&#x3b2;-Dependent EMT. Biomolecules. 2021;11:310. doi: 10.3390/biom11020310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11020310</ArticleId><ArticleId IdType="pmc">PMC7922523</ArticleId><ArticleId IdType="pubmed">33670735</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C., David V. Inflammation regulates fibroblast growth factor 23 production. Curr. Opin. Nephrol. Hypertens. 2016;25:325&#x2013;332. doi: 10.1097/MNH.0000000000000232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MNH.0000000000000232</ArticleId><ArticleId IdType="pmc">PMC5016608</ArticleId><ArticleId IdType="pubmed">27191351</ArticleId></ArticleIdList></Reference><Reference><Citation>Toro L., Michea L., Parra-Lucares A., Mendez-Valdes G., Villa E., Bravo I., Pumarino C., Ayala P., Sanhueza M.E., Torres R., et al. High Plasma Levels of Fibroblast Growth Factor 23 Are Associated with Increased Risk of COVID-19 in End-Stage Renal Disease Patients on Hemodialysis: Results of a Prospective Cohort. Toxins. 2023;15:97. doi: 10.3390/toxins15020097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins15020097</ArticleId><ArticleId IdType="pmc">PMC9963549</ArticleId><ArticleId IdType="pubmed">36828412</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov D.S. Therapeutic proteins. Methods Mol. Biol. 2012;899:1&#x2013;26. doi: 10.1007/978-1-61779-921-1_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-921-1_1</ArticleId><ArticleId IdType="pmc">PMC6988726</ArticleId><ArticleId IdType="pubmed">22735943</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovi&#x107; V., Szczepa&#x144;ska A., Berlicki &#x141;. Antiviral Protein-Protein Interaction Inhibitors. J. Med. Chem. 2024;67:3205&#x2013;3231. doi: 10.1021/acs.jmedchem.3c01543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.3c01543</ArticleId><ArticleId IdType="pmc">PMC10945500</ArticleId><ArticleId IdType="pubmed">38394369</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi C., Vanet A., Francesconi V., Tagliazucchi L., Tassone G., Venturelli A., Spyrakis F., Mazzorana M., Costi M.P., Tonelli M. Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. J. Med. Chem. 2023;66:3664&#x2013;3702. doi: 10.1021/acs.jmedchem.2c01229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01229</ArticleId><ArticleId IdType="pmc">PMC10005815</ArticleId><ArticleId IdType="pubmed">36857133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah D.K. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J. Pharmacokinet. Pharmacodyn. 2015;42:553&#x2013;571. doi: 10.1007/s10928-015-9447-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10928-015-9447-8</ArticleId><ArticleId IdType="pmc">PMC4593704</ArticleId><ArticleId IdType="pubmed">26373957</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi S.B., Samanta D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 2023;14:2411. doi: 10.1038/s41467-023-38039-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38039-x</ArticleId><ArticleId IdType="pmc">PMC10132957</ArticleId><ArticleId IdType="pubmed">37105998</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassman P.M., Balthasar J.P. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Drug Metab. Pharmacokinet. 2019;34:3&#x2013;13. doi: 10.1016/j.dmpk.2018.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dmpk.2018.11.002</ArticleId><ArticleId IdType="pmc">PMC6378116</ArticleId><ArticleId IdType="pubmed">30522890</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>